Medicare will cover controversial Alzheimer's drug Aduhelm with limits

Medicare will cover the controversial Alzheimer's drug Aduhelm but it will limit it to patients who enroll in a clinical study, officials announced Thursday.

Why it matters: The drug has been the center of a fierce battle between patient groups and members of Congress pushing for access, and members of the medical community questioning the lack of evidence supporting the drug's safety and efficacy.

• CMS is easing up on its initial plan which could have required a patient to undergo a randomized controlled trial in order to obtain the drug and will require a broader number of trials to access the drug.